logo-loader

CytomX Therapeutics shoots higher as it's set for US$200mln upfront payment from Bristol-Myers Squibb

Published: 10:32 20 Mar 2017 EDT

Cancerous cells
CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade

CytomX Therapeutics Inc (NASDAQ:CTMX) saw its shares shoot almost 25% higher in early New York trading after the biotech firm said it would receive a US$200mln upfront payment from drugs giant Bristol-Myers Squibb Co. (NYSE:BMY).

The payment is part of the expansion of a collaboration pact to discover cancer treatments using CytomX's Probody platform.

CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.

Bristol-Myers’ head of discovery, Carl Decicco, said: “CytomX's Probody platform has enhanced our discovery research as we seek to direct the therapeutic effects of immunotherapy in a more targeted approach against tumor.”

CytomX's shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 48 minutes ago